Sprint Bioscience AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was SEK 0.005 million compared to SEK 34.35 million a year ago. Revenue was SEK 0.02 million compared to SEK 33.9 million a year ago. Net loss was SEK 13.26 million compared to net income of SEK 17.57 million a year ago. Basic loss per share from continuing operations was SEK 0.33 compared to basic earnings per share from continuing operations of SEK 0.54 a year ago.
For the nine months, sales was SEK 0.068 million compared to SEK 34.38 million a year ago. Revenue was SEK 0.098 million compared to SEK 34.32 million a year ago. Net loss was SEK 45.37 million compared to SEK 10.04 million a year ago. Basic loss per share from continuing operations was SEK 1.14 compared to SEK 0.37 a year ago.